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Abstract
Background: In health economic evaluations, quality of life should be measured with preference-based utilities,
such as the EuroQol 5 Dimension 3-level (EQ-5D-3 L). Non-preference-based instruments (often disease-specific
questionnaires) are commonly mapped to utilities. We investigated if the relationship observed between the Patient
Assessment of Constipation Quality of Life (PAC-QOL) and the EQ-5D-3 L in patients with chronic idiopathic
constipation (CIC) also applies in opioid-induced constipation (OIC).
Methods: EQ-5D-3 L patient-level data from a clinical study of lubiprostone in OIC (n = 439) were scored using the
UK tariff. A published mapping between the PAC-QOL and the EQ-5D-3 L was tested using these data. New
mapping formulas were analysed, including PAC-QOL total and subscale scores. The root mean square error (RMSE),
the adjusted R2 and predicted/observed plots were used to test the fit.
Results: The utility measured with the EQ-5D-3 L was 0.450 ± 0.329, with a distinctly bimodal distribution. This
significantly improved if patients responded to treatment (defined as an increase of three spontaneous bowel
movements per week, with no rescue medication taken). The published mapping in CIC performed poorly in this
OIC population, and the PAC-QOL could not be reliably mapped on to the EQ-5D-3 L even when re-estimating
coefficients. This was shown in our two mappings (using PAC-QOL total score, and subscale scores) by a high RMSE
(0.317 and 0.314) and a low R2 (0.068 and 0.080), with high utilities underestimated and low utilities overestimated.
Conclusions: Patients with OIC have a low quality of life which does improve with the resolution of symptoms.
However the PAC-QOL cannot be used to estimate the EQ-5D-3 L utility – potentially as the PAC-QOL does not
capture the all relevant aspects of the patients quality of life (for example the cause of the opioid use).
Background
Although there are many potential causes of constipa-
tion, one of the most frequently reported is opioid usage:
opioid-induced constipation (OIC). The condition is
caused by opioids inhibiting the secretion of intestinal
fluids and suppressing the peristaltic propulsion of the
gastrointestinal tract, thereby slowing gastrointestinal
motility [1]. This opioid effect causes a range of symp-
toms, from difficulty evacuating faeces to straining, hard
stools, abdominal discomfort and bloating [2, 3].
Patient-reported quality of life in this disease area is
low – a poster by Iyer et al. showed OIC patients with
chronic non-cancer pain to have a baseline quality of life
of approximately 0.45 using the EuroQol 5 Dimension
3-level (EQ-5D-3 L) [4]. Similar values were reported for
a Dutch study, which estimated a median EQ-5D-3 L of
0.41 for constipated patients [5], although the cause of
the constipation is not stated. Dunlop et al. reported
that, using Short-Form 36 (SF-36) scores mapped to the
EQ-5D-3 L in an OIC population with chronic non-
cancer pain, patients had a utility of approximately 0.48
at baseline [6]. The existing literature suggests that the
low utilities observed may arise from the comorbid
conditions that necessitate long-term opioid therapy.
This may also explain why a time trade-off exercise
conducted with members of the UK general population
(n = 308) showed a higher utility for OIC itself, rating
the condition as having a utility of 0.74 [7].
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In cost–utility analyses, when no preference-based in-
struments (such as the EQ-5D-3 L or Health Utilities
Index) are available, mapping is a popular technique for
predicting health state utilities. In mapping, the relation-
ship between a non-preference-based instrument (often
a disease-specific questionnaire containing aspects on
quality of life) and a generic measure is estimated [8].
The Patient Assessment of Constipation Quality of Life
(PAC-QOL) is a commonly used disease-specific ques-
tionnaire, which contains questions on worries and con-
cerns, physical discomfort, psychosocial discomfort, and
satisfaction [9]. Searching the Oxford Mapping Database,
a study by Parker et al. reported a mapping between the
PAC-QOL and the EQ-5D-3 L utility in chronic idio-
pathic constipation (CIC), but no report on mapping in
OIC was found [10]. As CIC patients experience the
same symptoms (with the same endpoints and scales
used in clinical trials), our expectation was that a similar
relationship would exist between the PAC-QOL and
EQ-5D-3 L in OIC and CIC.
We investigated techniques for mapping PAC-QOL to
the EQ-5D-3 L utilities for patients with OIC, including
an exploration of the previously published mapping by
Parker et al. [10].
Methods
Description of study 1033
The analyses presented in this article are based on data
from Study 1033, which was a 12-week, double-blind,
randomised study of lubiprostone (n = 219) compared to
placebo (n = 220) [11]. Patients were enrolled with a
confirmed diagnosis of non-methadone OIC for chronic
non-cancer-related pain, who were having fewer than
three spontaneous bowel movements (SBMs) per week
and experiencing symptoms of constipation. Patients
had a mean age of 52, weight of 86 kg and 1.4 SBMs per
week. Both PAC-QOL and EQ-5D-3 L data were col-
lected. All patients had at least one medical diagnosis
that led to their opioid use. In general, these diagnoses
were musculoskeletal in origin, as shown in Table 1.
EQ-5D-3 L – a generic measure of health status
The EQ-5D-is widely used in health care and in clinical
research. As a preference-based instrument, the EQ-
5D-3 L is a recommended measure for use in health
economic evaluations. It takes the form of a descriptive
profile evaluation on five dimensions (mobility, self-care,
usual activities, pain/discomfort and anxiety/depression).
Each dimension is scored by the patient, with 1 indicating
no problems, 2 indicating some problems, and 3 indicat-
ing extreme problems. The total profile is valued with vali-
dated tariffs, resulting in preference-based utility scores
that can be used in economic evaluations – the UK tariff
was used in this study [12]. The final component of the
EQ-5D-3 L is the Visual Analogue Scale (VAS), a fixed
height bar on which participants are asked to mark their
self-rated health on a scale from 0 (‘worst imaginable
health state’) to 100 (‘best imaginable health state’). The
VAS, whilst collected in Study 1033, is not widely used in
the UK and was therefore not used in our analysis [13].
The PAC-QOL – a disease-specific instrument
In contrast with generic health instruments such as the
EQ-5D-3 L, the PAC-QOL is a disease-specific instrument
for patients with constipation developed by Marquis et al.
[9]. The PAC-QOL questionnaire provides a standardised
and validated assessment of the burden of constipation on
patients’ everyday functioning and well-being.
The questionnaire includes 27 questions, which cover
12 symptoms (identified from patient responses). These
12 symptoms are then divided into four subscales (wor-
ries and concerns, physical discomfort, psychosocial
discomfort, and satisfaction). Participants rate the ap-
plicability of each question over the previous 2 weeks
by selecting one of 5 boxes (broadly ranging from ‘Not
at all’, to ‘All of the time’). The scores for each question
are recoded as scores of 0–4, with lower scores indicat-
ing fewer problems. Symptom scores and sub-scores
are then calculated, as averages of the relevant ques-
tions, and symptoms, and the overall score computed
as the average score across the 12 symptoms.
Mapping between PAC-QOL and EQ-5D-3 L – the approach
by Parker et al
Parker et al. estimated the relationship between the gen-
eric EQ-5D-3 L and the disease-specific PAC-QOL score
in a severe CIC population [10]. The EQ-5D-3 L was
not directly measured in the study; instead the values
were mapped from a different instrument (the SF-36)
using the algorithm from Rowen et al. [14]. Three
Table 1 Summary of medical diagnoses in study 1033
Diagnosis group Total (n = 439)
Arthralgia 57 (13 %)
Arthritis 47 (10.7 %)
Back pain 228 (51.9 %)
Fibromyalgia 51 (11.6 %)
Intervertebral disc degeneration 110 (25.1 %)
Muscle spasms 53 (12.1 %)
Musculoskeletal pain 27 (6.2 %)
Neck pain 63 (14.4 %)
Osteoarthritis 121 (27.6 %)
Spinal column stenosis 85 (19.4 %)
Other 439 (100 %)
Note: Numbers sum to more than 100 % as patients may have more than
one condition
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mapping formulas were presented: one formula using
only the summary PAC-QOL score as an independent
variable, and two formulas using the PAC-QOL score
and the PAC-SYM score (a different questionnaire, the
Patient Assessment of Constipation Symptoms) as inde-
pendent variables. The statistic used to test the fit of the
mapping formulas was the root mean square error
(RMSE). We tested only the mapping between the EQ-
5D-3 L and the PAC-QOL, as the PAC-SYM was not
collected in the Study 1033.
Novel mapping formula
In addition to testing the validity of the mapping pub-
lished by Parker et al., we attempted to re-estimate the
parameters observed in the mapping using patient level
data from Study 1033. Two mapping formulas were ana-
lysed: the relationship between the EQ-5D-3 L and the
PAC-QOL total score (as in Parker et al. [10]); and the
relationship between the EQ-5D-3 L and PAC-QOL sub-
scale scores.
The statistics used to test the fit of the mapping for-
mulas were the RMSE and the adjusted R2 as well as
predicted versus observed plots. Mean utility and PAC-
QOL scores are presented as mean ± standard devi-
ation. All analyses were performed using the statistical
package R.
Results
Utility scores from study 1033
A total of 439 patients with OIC were included in Study
1033, with all except one patient completing the EQ-5D-
3 L (n = 438, 99.8 %). Figure 1 shows the distribution of
EQ-5D-3 L scores, which were distinctly bimodal. The
mean utility was 0.450 ± 0.329, with a median of 0.620
and a range from -0.239 to 1. Analysis of the dimension
scores showed that severe problems were primarily en-
countered by patients in the pain/discomfort dimension
of the EQ-5D-3 L (Fig. 2).
PAC-QOL scores were measured in all patients in
Study 1033, and showed an approximately normal distri-
bution with a mean overall score of 2.462 ± 0.651, a me-
dian overall score of 2.495 and a range from 0.739 to
3.938. The most severely impaired PAC-QOL subscore
was ‘satisfaction’, while the fewest problems were found
on the psychosocial subscore.
The primary efficacy endpoint in Study 1033 was the
overall SBM response rate, defined as having three or
more SBMs for at least 9 of 12 weeks, and at least one
additional SBM over mean baseline SBM during every
treatment week. At the end of treatment, patients with
three or more SBMs and not using rescue medication
in the previous week showed a higher utility than pa-
tients with fewer than three SBMs (0.46 ± 0.40 versus
0.34 ± 0.36, p = 0.012, Table 2). Similarly, overall PAC-
Fig. 1 Histogram of measured EQ-5D-3 L utilities in Study 1033
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QOL scores were lower, indicating better health, in pa-
tients with three or more SBMs compared to those with
fewer than three (1.21 ± 0.81 versus 2.09 ± 0.78, p <
0.001, Table 2).
Testing published mapping between EQ-5D-3 L and
PAC-QOL, and re-estimating parameters
The mapping formula given by Parker et al. [10] is:
Formula 1:
EQ‐5D‐3L ¼ 0:977 – 0:098  PAC‐QOL
When applying this formula, the predicted EQ-5D-3 L
compared poorly with the measured EQ-5D-3 L in Study
1033, shown in Fig. 3. In particular, low utilities were se-
verely overestimated by the formula, and the mean pre-
dicted utility was 0.74, much higher than the measured
utility of 0.45. The RMSE was 0.428, while the RMSE re-
ported by Parker et al. was 0.146.
We attempted to re-estimate the equation using the
patient level data from Study 1033, using a generalised
linear model in R to map the EQ-5D-3 L utility to the
PAC-QOL overall score. A second re-estimation was
then attempted using the same regression method, but
using the EQ-5D-3 L and the PAC-QOL subscales,
which then had interaction terms between all subscales
added to them. The results of these analyses showed that
there was a negative but highly variable correlation
between the PAC-QOL and the EQ-5D-3 L, with all
models showing a poor fit to the data. Estimating EQ-
5D-3 L using the PAC-QOL score as the only independ-
ent variable resulted in the following formula:
Formula 2:
EQ‐5D‐3L ¼ 0:780 ‐ 0:134  PAC‐QOL
The RMSE was 0.317 and the adjusted R2 was 0.068,
indicating a weak association between the PAC-QOL
and the EQ-5D-3 L. The mapping showed a poor fit to
the data; the high utilities were underestimated, and the
low utilities were overestimated (Fig. 4). Attempting a
mapping using the PAC-QOL subscales as independent
variables yielded:
Formula 3:
EQ‐5D‐3L ¼ 0:716 þ 0:023  Satisfaction– 0:091
 Physical þ 0:013
 Psychosocial– 0:062 Worries
The RMSE was 0.314 and the adjusted R2 was 0.080,
which, although an improved fit compared to the map-
ping using the PAC-QOL total score, still indicates a
weak association between the PAC-QOL and the EQ-
5D-3 L. The correlation plot was similar in appearance
to Fig. 4, where the high utilities were underestimated
and the low utilities were overestimated. Furthermore,
mapping did not significantly improve when interaction
terms were added between the subscale scores or when
alternative mappings were estimated in ranges of the
PAC-QOL score.
Discussion
The first notable finding of the analysis of EQ-5D-3 L at
baseline was the level of patient utility. This low utility is
consistent with the existing literature, where patients re-
port similar utilities [4–6].
Fig. 2 Percentage of patients reporting different levels in the EQ-5D-3 L dimensions
Table 2 EQ-5D-3 L utility and PAC-QOL by spontaneous bowel
movements per week
SBMs at EOT visita EQ-5D-3 L utility (mean ± sd) PAC-QOL
≥3 0.463 ± 0.356 1.211 ± 0.812
<3 0.395 ± 0.335 2.091 ± 0.784
Note: apatients using rescue medication in the previous week were classified
as having fewer than three SBMs
Key: EOT end of treatment, SBMs spontaneous bowel movements; sd,
standard deviation
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Fig. 3 Observed EQ-5D-3 L utility in Study 1033 compared to EQ-5D-3 L utility predicted by mapping from Parker et al. [10]
Fig. 4 Predicted and observed EQ-5D-3 L utility from Study 1033
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The mean utility of 0.450 is exceptionally low; it is
lower than in patients with comparable symptoms in CIC
[10] and even lower than the majority of EQ-5D-3 L esti-
mates in patients with advanced cancer, a condition that
we would have expected to be much more severe [15].
The main source of the low utility was the pain dimen-
sion, shown by the high scores on the pain/discomfort di-
mension of the EQ-5D-3 L scored by patients in Study
1033 (Fig. 2). This could be explained by the comorbid
conditions that resulted in long-term opioid therapy – in
Study 1033, the majority of patients were suffering from
several different diagnoses which all cause rheumatic pain
or pain of the musculoskeletal system (Table 1).
Although there was an association between high PAC-
QOL scores and lower EQ-5D-3 L utilities, it was not
possible to reliably map the PAC-QOL on to the EQ-
5D-3 L; the mapping formula provided by Parker et al.
proved unreliable in our study population [10]. A pos-
sible explanation for the failure of the mapping exercise
is that although the outcomes are the same (utility and
PAC-QOL scores), the trials were conducted in different
populations; the study by Parker et al. was in CIC, while
Study 1033 was in OIC with chronic non-cancer pain.
Although patients in both studies had a similar level of
constipation severity (as measured by the number of
spontaneous bowel movements), all patients in the
group receiving opioids had comorbid conditions leading
to the opioid use. This may have led to the poor scores
on the EQ-5D-3 L pain dimension. A second possible
explanation may be that Parker et al. did not directly
measure the EQ-5D-3 L in their study, but instead mea-
sured the SF-36, which was in turn mapped to the EQ-
5D-3 L. This two-step approach may have introduced a
different relationship between the PAC-QOL and the
EQ-5D-3 L, although the differences between patient
populations would have remained.
The mapping formulas directly estimated in this
study performed slightly better than the formula pro-
vided by Parker et al. However, these formulas still per-
formed poorly compared to other published mapping
studies [8, 16], as shown by the high RMSE and low R2
scores. Therefore, we would not recommend their use;
the mapping algorithms we used consistently underesti-
mated high utilities and overestimated low utilities, des-
pite the multiple methods attempted to obtain a better
fit. As such, the most likely explanation is that, in this
population, other factors, which are not captured by
the PAC-QOL, are the determinants of quality of life
(as measured by the EQ-5D-3 L utility). Similar conclu-
sions have been drawn for mapping studies with com-
parable instruments such as the Over-Active Bladder
Questionnaire [8]. Finally, while the mapping formula
of Parker et al. appeared to perform better in their
population of CIC (as demonstrated by a lower RMSE
statistic), other important fit criteria such as the R2 and
predicted versus observed plots were not presented.
Therefore, under/over-prediction cannot be assessed.
Conclusion
Mapping is a commonly used technique in the field of
health economics to derive generic utilities when only
disease-specific measures are available. In this analysis,
we applied an existing mapping between two instruments
to a related disease area. As a result, we showed that the
original mapping was a poor fit, and re-estimation proved
unsuccessful. In the absence of directly measured patient
utilities, caution should be exercised with regard to the
generalisability of mapping instruments in this area. While
the mapping by Parker et al. in CIC appears to demon-
strate a good fit between the PAC-QOL and the EQ-5D-
3 L in CIC [10], we found no such relationship in OIC.
However, our analysis shows that OIC patients with
chronic non-cancer pain exhibit a very low level of utility,
as consistently seen across the literature. It is likely that
the observed values relate not only to the condition under
investigation (OIC) but also to the underlying health is-
sues for which opioids are used. Regardless of origin, the
low quality of life of patients should be acknowledged.
Further research on the validity of mapping algorithms
is recommended, both in different datasets within the
same disease area (as validation), but also in related dis-
ease areas where the same instruments are used (as has
been done with the EORTC-QLQ-C30 and EQ-5D-3 L
[17]). Such work would ensure that published algorithms
are reproducible and give reliable results for use in
health economic evaluations.
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